20 May 2003
A prospective open study of extended lamivudine treatment in children with chronic hepatitis B unresponsive to previous interferon alpha therapy
D. Lebensztejn, E. Skiba, O. Kovalchuk, M. Kaczmarski, L. ChyczewskiMed Sci Monit 2003; 9(2): 11-0 :: ID: 15252
Abstract
Background:Lamivudine is an inhibitor of HBV replication which is efficient and well tolerated in adults with chronic hepatitis B.Data regarding the effect of extended Lamivudine treatment in children who failed to respond to previous IFN a therapy are scarce.Therefore,the effects of Lamivudine treatment on ALT activity,HBV DNA,HBeAg and HBsAg seroconversion as well as the occurence of YMDD variant and adverse effects were determined.Material/Methods:The observation was carried out on 41 children,aged 4 –17 years,with biopsy-proven chronic hepatitis B (HBeAg+,HBV DNA+,wild-type virus+),who were nonresponders to previous IFN a therapy.Lamivudine in the dose of 3 –4 mg/kg/day up to 100mg/day was given for 18 months.Results:40 children completed 12 months and 25 of them –18 months of therapy;one boy was excluded from this study due to severe thrombocytopenia.After 6 months of Lamivudine therapy 62.2%of children cleared HBV DNA,59.3% normalized AlAT activity and only 1 child (2.5%)lost HBeAg. After a year of therapy 25%of children cleared HBV DNA, 81.5% normalized ALT activity and 10%lost HBeAg.At the end of 18 months therapy in the group of 25 children 40%of them cleared HBV DNA,20%seroconverted to antiHBe and 76.5%normalized ALT activity.No adverse effects were noted, except thrombocytopenia.YMDD variant was present in 20% of children after one year of therapy and in 32%–6 months later. Conclusions:The 18-month-treatment with Lamivudine in children with chronic hepatitis B who did not respond to IFN a normalized ALT activity in most children and caused seroconversion to antiHBe in 20%.However it was associated with a high risk for developing YMDD mutation.
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952